Dermata Therapeutics, Inc. (NASDAQ:DRMAW) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMAW) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 1,600 shares, a drop of 38.5% from the August 31st total of 2,600 shares. Based on an average trading volume of 1,900 shares, the days-to-cover ratio is presently 0.8 days. Based on an average trading volume of 1,900 shares, the days-to-cover ratio is presently 0.8 days.

Dermata Therapeutics Trading Down 26.7%

DRMAW opened at $0.02 on Monday. The firm’s fifty day moving average is $0.02 and its two-hundred day moving average is $0.02. Dermata Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.04.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.